MENU
+Compare
CMOPF
Stock ticker: OTC
AS OF
May 28 closing price
Price
$64.37
Change
+$9.37 (+17.04%)
Capitalization
827.91M

CMOPF Cosmo Pharmaceuticals NV Forecast, Technical & Fundamental Analysis

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech... Show more

CMOPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CMOPF with price predictions
Jul 03, 2025

Aroon Indicator for CMOPF shows an upward move is likely

CMOPF's Aroon Indicator triggered a bullish signal on July 02, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 87 similar instances where the Aroon Indicator showed a similar pattern. In of the 87 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for CMOPF crossed bullishly above the 50-day moving average on June 02, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CMOPF turned negative on June 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 18 similar instances when the indicator turned negative. In of the 18 cases the stock turned lower in the days that followed. This puts the odds of success at .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.701) is normal, around the industry mean (5.632). P/E Ratio (68.493) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.004). Dividend Yield (0.023) settles around the average of (0.161) among similar stocks. CMOPF's P/S Ratio (7.107) is slightly higher than the industry average of (3.643).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CMOPF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMOPF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.

View a ticker or compare two or three
CMOPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
Sir John Rogerson’s Quay
Phone
+353 18170370
Employees
295
Web
https://www.cosmopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRAGX104.76N/A
N/A
Bridgeway Aggressive Investors 1
OTCFX56.94N/A
N/A
T. Rowe Price Small-Cap Stock
NWJFX111.65N/A
N/A
Nationwide NYSE Arca Tech 100 Idx InsSvc
LADVX28.99N/A
N/A
Lord Abbett Developing Growth R6
AISHX6.00N/A
N/A
Aristotle Small/Mid Cap Equity C

CMOPF and Stocks

Correlation & Price change

A.I.dvisor tells us that CMOPF and GSK have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CMOPF and GSK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMOPF
1D Price
Change %
CMOPF100%
N/A
GSK - CMOPF
22%
Poorly correlated
-0.86%
NVS - CMOPF
21%
Poorly correlated
-1.54%
CHGCY - CMOPF
7%
Poorly correlated
-0.89%
DSNKY - CMOPF
5%
Poorly correlated
-2.41%
CSPCY - CMOPF
4%
Poorly correlated
+4.50%
More